What Is Synopsys, Inc.'s (NASDAQ:SNPS) Share Price Doing?

Synopsys, Inc. (NASDAQ:SNPS) saw a decent share price growth of 15% on the NASDAQGS over the last few months. The company is inching closer to its yearly highs following the recent share price climb. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Let’s examine Synopsys’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

Check out our latest analysis for Synopsys

Advertisement

What's The Opportunity In Synopsys?

Synopsys appears to be expensive according to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average. We’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 63.05x is currently well-above the industry average of 42.22x, meaning that it is trading at a more expensive price relative to its peers. But, is there another opportunity to buy low in the future? Given that Synopsys’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What does the future of Synopsys look like?

earnings-and-revenue-growth
NasdaqGS:SNPS Earnings and Revenue Growth May 27th 2024

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 49% over the next couple of years, the future seems bright for Synopsys. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? It seems like the market has well and truly priced in SNPS’s positive outlook, with shares trading above industry price multiples. At this current price, shareholders may be asking a different question – should I sell? If you believe SNPS should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping an eye on SNPS for a while, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the positive outlook is encouraging for SNPS, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

If you want to dive deeper into Synopsys, you'd also look into what risks it is currently facing. You'd be interested to know, that we found 1 warning sign for Synopsys and you'll want to know about it.

If you are no longer interested in Synopsys, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:SNPS

Synopsys

Provides design IP solutions in the semiconductor and electronics industries.

Reasonable growth potential with mediocre balance sheet.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5362.1% undervalued
132 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18053.7% undervalued
3 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.324.1% undervalued
4 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2450.4% undervalued
21 users have followed this narrative
1 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

OI
MVO logo
Oily on MV Oil Trust ·

Poor analysis here will mislead investors

Fair Value:US$2.11.0% undervalued
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ZH
zhalia
LYC logo
zhalia on Lynas Rare Earths ·

Lynas Rare Earths to Shine with 281% Future P/E Surge

Fair Value:AU$22.8714.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
ROP logo
kapirey on Roche Holding ·

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Fair Value:CHF 353.349.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.1% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.227.7% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9327.4% undervalued
1399 users have followed this narrative
2 users have commented on this narrative
12 users have liked this narrative